Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05965752 · ClinicalTrials.gov registry record · NA
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 328
- Enrollment target
NCT05965752: Completed NA study, sponsored by Duke University.
NCT05965752 is a NA study that has completed, run by Duke University. The registered enrollment target is 328 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05965752, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 328 participants
- Enrollment target
Study Summary
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating potential interventions for PASC-mediated cognitive dysfunction. The hypothesis is that PASC associated dysfunction in cognitive domains, such as executive function and attention, may be improved by interventions that selectively focus on enhancing those domains.
Primary Outcome
Appendix-specific outcome measure data will be reported under the associated NCT ID.
Interventions
- OTHER BrainHQ/Active Comparator Activity
- OTHER BrainHQ
- OTHER PASC CoRE
- DEVICE tDCS-active
- DEVICE tDCS-sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2024-06-10 |
| Phase | NA |
What the finished NCT05965752 record still lists
NCT05965752 is an interventional study that assigns participants to a tested intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 5 interventions - of which BrainHQ/Active Comparator Activity is the first listed.
NCT05965752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05965752 about?
NCT05965752 is a clinical study titled "RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms". This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-ce...
What is the current status of trial NCT05965752?
This trial is currently completed. It is a NA study. The enrollment target is 328 participants. The study started on 2023-09-01. Estimated completion is 2024-06-10.
What interventions are being tested in trial NCT05965752?
The interventions under investigation include: BrainHQ/Active Comparator Activity (OTHER), BrainHQ (OTHER), PASC CoRE (OTHER), tDCS-active (DEVICE), tDCS-sham (DEVICE).
Who is sponsoring clinical trial NCT05965752?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05965752's enrollment target sits among peer trials
328 308th of 2000 higher than 1,692 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
- NCT05548413 · 328 participants · NA
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
- NCT06393725 · 328 participants · NA
Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI